Theradaptive Closes $26 Million Series A Investment Round
06/15/23, 1:04 PM
Location
frederickMoney raised
$26 million
Industry
biotechnology
health care
Round Type
series a
Today, Theradaptive, a biopharmaceutical company breaking new ground in targeted regenerative therapeutics, announces that it has closed a $26 million Series A funding round to advance development of its targeted regenerative therapeutics.
Company Info
Location
frederick, maryland, united states
Additional Info
Theradaptive is a privately held, clinical-stage biologics company developing protein therapeutics for spine, orthopedics, dental, and soft tissue repair and targeted therapeutics in diverse areas such as immuno-oncology. The company leverages its therapeutic delivery platform to deliver recombinant biologics to targeted areas in the body with high precision and persistence to address unmet medical needs.